SCHEMBL4162671

SCHEMBL4162671

O=C(Nc1cc(Cl)cnc1Cl)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 12/20 0.47
RAB9A P51151 1/20 0.40
GSK3A P49840 3/20 0.39
DHODH Q02127 2/20 0.38
MAPK13 O15264 1/20 0.38
GCGR P47871 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38
JAK2 O60674 1/20 0.38
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38
TYK2 P29597 1/20 0.38
SYK P43405 1/20 0.38
CDK5 Q00535 1/20 0.38
PRKCQ Q04759 1/20 0.38
AURKB Q96GD4 1/20 0.38
AKT1 P31749 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166762 0.90 GSK3B (0.48) GSK3BRAB9AGSK3A
SCHEMBL4148346 0.86 RAB9A (0.53) GSK3BRAB9A
SCHEMBL4148260 0.84 GSK3B (0.55) GSK3BGSK3AMAPK14JAK2PIM1
SCHEMBL4145800 0.83 GSK3B (0.52) GSK3BGSK3A
SCHEMBL4148349 0.82 GSK3B (0.46) GSK3B
SCHEMBL4153157 0.82 GSK3B (0.48) GSK3BGSK3ADHODHMAPK13GCGR
SCHEMBL8237740 0.81 GSK3B (0.47) GSK3BMAPK14
SCHEMBL4152183 0.81 GSK3B (0.56) GSK3B
SCHEMBL4145763 0.80 GSK3B (0.53) GSK3BGSK3ADHODHMAPK13GCGR
SCHEMBL4154229 0.80 GSK3B (0.51) GSK3BRAB9AGSK3ADHODHMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885RAB9A 2749/4885GSK3A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.